Solriamfetol

Solriamfetol

SCHEMBL42526

NC(=O)OCC(N)Cc1ccccc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
EPHX1 P07099 2/20 0.55
MMP2 P08253 4/20 0.53
ALPI P09923 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC7A5 Q01650 1/20 0.52
LMNA P02545 1/20 0.50
SCN4A P35499 2/20 0.49
ANPEP P15144 1/20 0.48
SRR Q9GZT4 2/20 0.47
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
TACR1 P25103 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Solriamfetol SCHEMBL2739637 1.00 PKM (0.56) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL30929348 1.00 PKM (0.56) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL30929349 1.00 PKM (0.56) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL42525 1.00 PKM (0.56) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL8430382 0.98 PKM (0.54) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL28413501 0.98 PKM (0.54) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL4987496 0.98 PKM (0.54) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL8426383 0.98 PKM (0.54) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL30518836 0.97 PKM (0.53) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1
Solriamfetol SCHEMBL30518840 0.95 PKM (0.51) PKMCYP1A2CYP2D6SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688731-A1 PROCESS FOR PREPARING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE INKE, S.A. (ES) 2026-02-11 EP claimed
US-12497353-B2 Process for the purification of (R)-2-amino-3-phenylpropyl carbamate FLAMMA SPA (IT) 2025-12-16 US claimed
US-20250352476-A1 FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AXSOME MALTA LTD (MT) 2025-11-20 US claimed
US-12390419-B2 Formulations of (R)-2-amino-3-phenylpropyl carbamate AXSOME MALTA LTD. (MT) 2025-08-19 US claimed
US-20250114322-A1 METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-04-10 US claimed
WO-2024208791-A1 PROCESS FOR PREPARING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE INKE, S.A. (ES) 2024-10-10 WO claimed
US-20240285538-A1 FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-08-29 US claimed
US-20240239740-A1 TREATMENT OF SLEEP-WAKE DISORDERS SK BIOPHARMACEUTICALS CO LTD (KR) 2024-07-18 US claimed
US-20240189270-A1 METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS AXSOME MALTA LTD (MT) 2024-06-13 US claimed
US-20240180866-A1 METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS HERCULES CAPITAL, INC. 2024-06-06 US claimed
US-20100331332-A1 METHODS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR SK HOLDINGS CO., LTD. (KR) 2010-12-30 US claimed
WO-2010150995-A2 COMPOSITIONS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR SK HOLDINGS CO., LTD. (KR) 2010-12-29 WO claimed
US-20090312416-A1 TREATMENT OF SLEEP-WAKE DISORDERS SK HOLDINGS CO., LTD. (KR) 2009-12-17 US claimed
CN-101557804-A Phenylalkylamino carbamate compositions JANSSEN PHARMACEUTICA NV (BE) 2009-10-14 CN claimed
EP-2079449-A2 PHENYLALKYLAMINO CARBAMATE COMPOSITIONS Janssen Pharmaceutica, N.V. (BE) 2009-07-22 EP claimed
CN-101217949-A Treating Sleep-Wake Disorders SK CORP (KR) 2008-07-09 CN claimed
WO-2008048801-A2 PHENYLALKYLAMINO CARBAMATE COMPOSITIONS JANSSEN PHARMACEUTICA NV (BE) 2008-04-24 WO claimed
US-20080090902-A1 PHENYLALKYLAMINO CARBAMATE COMPOSITIONS JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-17 US claimed
EP-1890684-A1 TREATMENT OF SLEEP-WAKE DISORDERS SK Holdings Co., Ltd. (KR) 2008-02-27 EP claimed
WO-2006133393-A1 TREATMENT OF SLEEP-WAKE DISORDERS SK HOLDINGS CO., LTD. (KR) 2006-12-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240285538-A1 FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE PRCP, GRPR, CPS1 PKM 2187/4885CYP1A2 1001/4885CYP2D6 946/4885
US-12390419-B2 Formulations of (R)-2-amino-3-phenylpropyl carbamate PRCP, GRPR, CPS1 PKM 2187/4885CYP1A2 1001/4885CYP2D6 946/4885
US-20250114322-A1 METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS CHAT, PNMT, HCRTR1 PKM 1169/4885CYP1A2 1015/4885CYP2D6 2042/4885
US-20080090902-A1 PHENYLALKYLAMINO CARBAMATE COMPOSITIONS CA2, PKD1, CA4 PKM 2121/4885CYP1A2 4419/4885CYP2D6 2932/4885
US-20100331332-A1 METHODS FOR TREATING DRUG ADDICTION AND IMPROVING ADDICTION-RELATED BEHAVIOR CES2, SLC6A3, CHAT PKM 2523/4885CYP1A2 3069/4885CYP2D6 3192/4885
US-20250352476-A1 FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE CPS1, PRCP, GLS2 PKM 1586/4885CYP1A2 527/4885CYP2D6 392/4885
US-20240239740-A1 TREATMENT OF SLEEP-WAKE DISORDERS HCRTR1, HCRTR2, MTNR1B PKM 3390/4885CYP1A2 119/4885CYP2D6 264/4885
US-12497353-B2 Process for the purification of (R)-2-amino-3-phenylpropyl carbamate PHYKPL, BPHL, DNPEP PKM 602/4885CYP1A2 2295/4885CYP2D6 1898/4885
US-20240180866-A1 METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS CHAT, PNMT, HCRTR1 PKM 1169/4885CYP1A2 1015/4885CYP2D6 2042/4885
US-20090312416-A1 TREATMENT OF SLEEP-WAKE DISORDERS HCRTR1, HCRTR2, MTNR1B PKM 3390/4885CYP1A2 119/4885CYP2D6 264/4885
US-20240189270-A1 METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS CHAT, PNMT, HCRTR1 PKM 1169/4885CYP1A2 1015/4885CYP2D6 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.